[go: up one dir, main page]

UY37534A - Metodo para el tratamiento de enfermedades fibroticas utilizando el interferon-lambda - Google Patents

Metodo para el tratamiento de enfermedades fibroticas utilizando el interferon-lambda

Info

Publication number
UY37534A
UY37534A UY0001037534A UY37534A UY37534A UY 37534 A UY37534 A UY 37534A UY 0001037534 A UY0001037534 A UY 0001037534A UY 37534 A UY37534 A UY 37534A UY 37534 A UY37534 A UY 37534A
Authority
UY
Uruguay
Prior art keywords
treatment
interferon
lambda
fibrotic diseases
fibrosis
Prior art date
Application number
UY0001037534A
Other languages
English (en)
Inventor
Scott Johnson Thimothy
Breda Twomey
Janine Powers
Original Assignee
Ucb Biopharma Sprl Y Five Prime Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ucb Biopharma Sprl Y Five Prime Therapeutics Inc filed Critical Ucb Biopharma Sprl Y Five Prime Therapeutics Inc
Publication of UY37534A publication Critical patent/UY37534A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención se refiere a métodos para el tratamiento de la fibrosis. La invención describe una nueva investigación que demuestra que el interferón lambda tiene efectos antifibróticos que actúan directamente tanto in vitro como in vivo y puede usarse para proporcionar nuevas terapias eficaces para el tratamiento de múltiples tipos de la fibrosis
UY0001037534A 2016-12-20 2017-12-20 Metodo para el tratamiento de enfermedades fibroticas utilizando el interferon-lambda UY37534A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1621728.3A GB201621728D0 (en) 2016-12-20 2016-12-20 Methods

Publications (1)

Publication Number Publication Date
UY37534A true UY37534A (es) 2018-09-28

Family

ID=58284677

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001037534A UY37534A (es) 2016-12-20 2017-12-20 Metodo para el tratamiento de enfermedades fibroticas utilizando el interferon-lambda

Country Status (13)

Country Link
US (2) US20190374610A1 (es)
EP (1) EP3558342B1 (es)
JP (3) JP7609556B2 (es)
CN (1) CN110381985A (es)
AR (1) AR110404A1 (es)
BR (1) BR112019012084A2 (es)
CA (1) CA3044949A1 (es)
EA (1) EA201991175A1 (es)
ES (1) ES3019566T3 (es)
GB (1) GB201621728D0 (es)
TW (1) TW201828973A (es)
UY (1) UY37534A (es)
WO (1) WO2018115199A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3824906A1 (en) 2016-12-21 2021-05-26 Amgen Inc. Anti-tnf alpha antibody formulations
ES3015227T3 (en) * 2017-03-16 2025-04-30 Evangelos Andreakos Use of lambda interferons in the treatment of an obesity-related disorder, atherosclerosis or a coagulation disorder
WO2020041636A1 (en) * 2018-08-23 2020-02-27 Exalt Therapeutics, Llc Modified ifnl3 polypeptides comprising a pharmacokinetic enhancing moiety and their uses
WO2021009332A1 (en) 2019-07-18 2021-01-21 Enyo Pharma Method for decreasing adverse-effects of interferon
CN110882381B (zh) * 2019-12-18 2020-11-17 中国人民解放军陆军军医大学第一附属医院 重组IFN-λ1蛋白在制备防治炎症性骨丢失药物中的应用
US20220378878A1 (en) * 2019-12-20 2022-12-01 The Council Of The Queensland Institute Of Medical Research Treatment of gastrointestinal disease
CN114736878B (zh) * 2021-01-07 2024-04-19 秦皇岛摩登狗生物科技有限公司 共表达猪干扰素l3和猪白介素22重组杆状病毒及应用

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9113120D0 (en) 1991-06-18 1991-08-07 Kodak Ltd Photographic processing apparatus
CA2443277A1 (en) 2001-04-06 2002-10-17 Maxygen Holdings Ltd. Interferon gamma polypeptide variants
JP2006502152A (ja) 2002-08-28 2006-01-19 インターミューン インコーポレイテッド 線維性疾患治療用の併用療法
WO2004078194A1 (en) 2003-02-28 2004-09-16 Intermune, Inc. Interferon drug therapy for the treatment of viral diseases and liver fibrosis
EP1596883A1 (en) 2003-02-28 2005-11-23 Intermune, Inc. Interferon drug therapy for the treatment of viral diseases and liver fibrosis
WO2004105684A2 (en) 2003-05-16 2004-12-09 Intermune, Inc. Combination therapy for proliferative disorders
CA2527020A1 (en) 2003-07-01 2005-01-13 Celltech R & D Limited Modified antibody fab fragments
GB0315457D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
GB0315450D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
US20070258946A1 (en) * 2003-12-23 2007-11-08 Blatt Lawrence M Combination Therapy for Treating Hepatitis C Virus Infection
WO2005110478A2 (en) 2004-04-13 2005-11-24 Intermune, Inc. Combination therapy for treating fibrotic disorders
GB0411186D0 (en) 2004-05-19 2004-06-23 Celltech R&D Ltd Biological products
US7597884B2 (en) 2004-08-09 2009-10-06 Alios Biopharma, Inc. Hyperglycosylated polypeptide variants and methods of use
JP2009529027A (ja) 2006-03-08 2009-08-13 ビオメトード ヒトインターフェロンガンマ（ＩＦＮγ）変異体
ES2667729T3 (es) 2007-09-26 2018-05-14 Ucb Biopharma Sprl Fusiones de anticuerpos con doble especificidad
RU2496514C2 (ru) 2008-06-05 2013-10-27 Займоджинетикс, Инк. Применение пэгилированных интерферонов типа iii для лечения гепатита с
WO2010045261A1 (en) 2008-10-13 2010-04-22 Zymogenetics, Llc Single chain fc type iii interferons and methods of using same
EP2364159A4 (en) 2008-10-23 2012-06-13 Concert Pharmaceuticals Inc DETERIORIC MACROCYCLIC INHIBITORS OF NS3 VIRAL PROTEASE
US20110243888A1 (en) * 2008-11-20 2011-10-06 Sheppard Paul O Il-29 mutants and uses thereof
WO2011075605A2 (en) 2009-12-18 2011-06-23 Alios Biopharma, Inc. Hyperglycosylated interferon variants and methods of use
IT1400236B1 (it) 2010-05-10 2013-05-24 Univ Bari Impiego di composti noti per il trattamento dell'insufficienza renale cronica(irc)
CN102584979B (zh) * 2011-01-18 2015-10-14 北京凯因科技股份有限公司 PEG化干扰素λ
AU2013240301B2 (en) 2012-03-28 2017-10-05 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services A novel interferon-lambda4 (IFNL4) protein, related nucleic acid molecules, and uses thereof
KR20180110127A (ko) 2016-02-19 2018-10-08 아이거 바이오파마슈티컬스 인코포레이티드 인터페론 람다를 이용한 델타 간염 바이러스 감염의 치료

Also Published As

Publication number Publication date
US20190374610A1 (en) 2019-12-12
GB201621728D0 (en) 2017-02-01
JP2020511415A (ja) 2020-04-16
TW201828973A (zh) 2018-08-16
US20240000893A1 (en) 2024-01-04
EP3558342A1 (en) 2019-10-30
JP2022081677A (ja) 2022-05-31
EP3558342B1 (en) 2025-01-29
JP7609556B2 (ja) 2025-01-07
EA201991175A1 (ru) 2019-11-29
ES3019566T3 (en) 2025-05-20
CN110381985A (zh) 2019-10-25
WO2018115199A1 (en) 2018-06-28
BR112019012084A2 (pt) 2019-11-12
AR110404A1 (es) 2019-03-27
US11975046B2 (en) 2024-05-07
JP2024156844A (ja) 2024-11-06
CA3044949A1 (en) 2018-06-28

Similar Documents

Publication Publication Date Title
UY37534A (es) Metodo para el tratamiento de enfermedades fibroticas utilizando el interferon-lambda
IL290809B1 (en) Tau-protein targeted protacs and related methods of use
EA201790398A1 (ru) Способы лечения заболевания печени
MX2018006578A (es) Formulaciones farmaceuticas topicas para tratar afecciones inflamatorias.
MX370506B (es) Método para tratar trastorno de estrés post-traumático.
GT201700081A (es) Moléculas de anticuerpo que se unen a pd-l1 y usos de las mismas
MX386886B (es) Combinación de anticuerpos anti-cd38 y ácido todo-trans retinoico para usarse en terapias.
GT201600185A (es) Moléculas de anticuerpo que se unen a lag-3 y usos de las mismas
MX373045B (es) Inhibidores de mdm2 y metodos terapeuticos que utilizan el mismo.
NI201600071A (es) Compuestos de inhibidor de autotaxina
EA201691582A1 (ru) Новые фармацевтические препараты
MX2015009058A (es) Composiciones y metodos para tratar la inflamacion cronica y las enfermedades inflamatorias.
HRP20181169T1 (hr) Predlijekovi fumarata i njihova upotreba u liječenju različitih bolesti
CL2015002807A1 (es) Terapia de combinación
UY34675A (es) ?proceso y aparato para tratar superficies de metal?.
MX2019009783A (es) Metodo para fabricar una barra que comprende antitranspirante.
UY36920A (es) Formulaciones de aminoácidos de liberación modificada administradas por vía oral
IL269158A (en) Compositions and methods for treating inflammatory diseases
MX2019005299A (es) Anticuerpos anti-receptor del factor de crecimiento de tipo insulinico humano 1 (anti-igf-1r) con abolicion de la union al fcrn y su uso en el tratamiento de enfermedades oculares vasculares.
CR20150637A (es) Tratamiento de enfermedades miopaticas y neurodegenerativas por agregación de proteina mediante administración parenteral
NI201600070A (es) Inhibidores tetracíclicos de autotaxina
MX2019005779A (es) Metodos para tratar trastornos del desarrollo y/o trastornos convulsivos con flupirtina.
CL2016001098A1 (es) Uso de cisteamina y sus derivados para el tratamiento de enfermedades mitocondriales
CL2015002181A1 (es) Tratamiento de formas progresivas de esclerosis múltiple con laquinimod.
MX2018012230A (es) Métodos para tratar enfermedades oculares.

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20230705